100% recovered and discharged from the hospital! Coagulant pathway inhibitor treatment COVID-19 showed strong efficacy.

Read: Omeros recently published the results of a sympathetic drug study on the treatment of PATIENT-19 acute respiratory distress syndrome (ARDS) patients at narsoplimab.
Omeros recently released the results of a sympathetic drug study on the treatment of patients with COVID-19 acute respiratory distress syndrome (ARDS) at narsoplimab.
Narsoplimab is a monoclonal antibody that targets glycosin-binding coagulation-related serine protease-2 (MASP-2), a study involving six patients with COVID-19 with ARDS, all of which required mechanical aeration before treatment, and after treatment with narsoplimab, all patients recovered, survived and were discharged from the hospital.
addition, narsoplimab therapy is associated with rapid and sustained improvement of all evaluation indicators of endotheskin/cell damage and/or inflammation.
Omeros jumped 50 per cent after the results were released.
In patients with COVID-19, ARDS and thrombosis events are common life-threatening complications, and autopsies usually show arterial thrombosis and severe endotring damage, while endothial cell damage play an early and central role in ARDS and thrombosis.
endoskin cell damage can activate the complement coagulation pathway, MASP-2 is the effect enzyme of the coagulation pathway, and is also the target of narsoplimab.
MASP-2 binds to SARS-CoV-2's nuclear shell protein, leading to complement activation and lung damage.
has published a large number of articles detailing and further confirming the central role of endoskin damage, complement system activation, coagulation pathways and thrombosis in COVID-19.
in addition to COVID-19, narsoplimab is also used to treat hematopoietic stem cell transplant-related thrombosis (HSCT-TMA), another deadly thrombosis that often causes endoskin damage.
In key HSCT-TMA trials, patients treated with narsoplimab improved significantly in both laboratory and clinical endpoints, with an unexpectedly high survival rate: 100 days of survival, 20 percent expected by medical experts, and up to 83 percent of patients treated at least 4 weeks of narsoplimab as prescribed by the program.
, the FDA had granted narsoplimab a breakthrough drug for the treatment of HSCT-TMA.
, Omeros is rolling through the BLA of narsoplimab.
in addition to inhibiting the activation of the coagulation pathway, narsoplimab can also block thrombosis associated with microvascular injury and activation of MASSP-2-mediated clotting enzymes, kinetic peptide release enzymes and factor XII.
these unique anticoagulant effects may provide therapeutic benefits for HSCT-TMA and COVID-19.
, narsoplimab does not affect the classical pathways and adaptive immune response of the complement system and therefore does not increase the risk of infection.
the sympathetic drug study was initiated at the request of Alessandro Rambaldi, a professor of hematology at the University of Milan and lead investigator on the key trial of narsoplimab's treatment of HSCT-TMA.
given the clinical and pathological similarities between COVID-19 and HSCT-TMA, Rambaldi requested that patients be treated at their hospital, Bergamo Hospital in Italy.
the study used a coagulation pathway inhibitor to treat COVID-19 for the first time, with a total of 6 patients with ARDS requiring continuous cylindrative pressure (CPAP) or intuperation receiving narsoplimab treatment.
57 years (47-63 years old), 83% were male, and all had merging disorders.
At baseline examination, circulating endoskine cell counts and serum leukocyte interleuclein-6 (IL-6), leukocyte mesokine-8 (IL-8), C-reactive proteins (CRP), lactic acid dehydrogenase (LDH), D-dispolymers, and acetone transaminase (AST) - markers of all endoskin/cell damage and/or inflammation - significantly increased serum levels.
narsoplimab treatment is started within 48 hours of the start of mechanical aeration and is given twice a week for 2-4 weeks.
results showed that all patients recovered, survived and were discharged from the hospital.
Narsoplimab therapy is associated with a rapid and continuous decrease in all evaluation indicators of endoskin/cell damage and/or inflammation (CEC, IL-6, IL-8, CRP, LDH, D-D-djumer, and AST).
patterns of laboratory markers were consistent with observed clinical improvements.
, CEC counting appears to be a reliable tool for assessing endothy injuries and treatment responses.
the time-improvement effects of IL-6 and IL-8 after Narsoplimab therapy showed that in COVID-19, the activation of the coagulation pathway may be higher than that of cytokines, and that coagulation pathway inhibition had a beneficial effect on cytokine storms in patients infected with COVID-19.
Two patients (one requiring intuperation and the other receiving CPAP) were further complicated by a large number of double pulmonary thrombosis, and both patients recovered after receiving narsoplimab treatment, possibly benefiting from the anticoagulant effect of the drug.
studies, narsoplimab was well-resistant and no adverse reactions were reported.
two control groups with similar patient entry criteria and baseline characteristics were used for retrospective comparison, showing mortality rates of 32 percent and 53 percent, respectively.
, Omeros has made progress in discussions with U.S. government agencies about funding to accelerate mass production of narsoplimab, with the aim of making narsoplimab treatment available to a wider range of COVID-19 patients, as well as providing narsoplimab for other COVID-19-related programs in the U.S. government.
: 1, Omeros Powers on positive narsoplimab data in severely ill COVID-19 patients2, Endothelial Injury and Thrombotic Microangiopathy in COVID-19: Treatment with the Lectin-Path Restoor Narsoplimab.